Incorrect Data in Abstract and Figure

In the Original Investigation titled “Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy,”¹ published in the February 7, 2023, issue of JAMA, 3 items were published incorrectly. In the Abstract, the severity level of 43 to 53 for the Early Treatment Diabetic Retinopathy Study (EDTRS) was correct, but it should not have shown a range explaining best and worst scores. A comma was inserted into the Conclusion sections of the Abstract and the text to clarify meaning: “Among patients with NPDR but without CI-DME, at 4 years treatment with aflibercept vs sham, initiating aflibercept treatment only if vision-threatening complications developed, resulted in statistically significant anatomic improvement but no improvement in visual acuity.” In Figure 1, numeric values indicating inclusion in the per-protocol analyses were incorrectly reported. For eyes randomized to receive aflibercept, 163 were included in the per-protocol analysis for the key anatomical outcome and 106 were included in the per-protocol analysis for the visual acuity outcome. For eyes randomized to receive sham, 164 were included in the per-protocol analysis for the key anatomical outcome and 90 were included in the per-protocol analysis for the visual acuity outcome. This article was corrected online.